KBC Group
CTIC

KBC Group’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

KBC Group’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-14,325
Closed -$42K – 1362
2021
Q3 		$42K Sell
14,325
-15,622
-52% -$42.5K ﹤0.01% 1253
2021
Q2 		$75K Buy
+29,947
New +$71.8K ﹤0.01% 1200

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

KBC Group's CTIC Position: Q4 2021 in Review

KBC Group sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2021, closing a stake of 14,325 shares — an estimated $42K sold.

KBC Group first reported a position in CTIC in Q2 2021 and held it in 2 quarters. The position peaked at $75K in Q2 2021. 63 funds tracked by Wall St. Rank hold CTIC as of Q4 2021.

  • KBC Group reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2021 after selling out during the quarter.
  • KBC Group sold 14,325 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2021, an estimated $42K.
  • KBC Group first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2021 and held it in 2 quarters.
  • KBC Group's CTI BioPharma Corp. (DE) Common Stock position peaked at $75K in Q2 2021.
  • 63 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2021.

Based on KBC Group's 13F filing for Q4 2021, filed 3 Feb 2022.